NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B or 2C AGONISTS
AssigneeLDN Pharma Limited
InventorsWai Liu, Ian Thompson, Francis Hood
Life of this patent
Estimating the term…
Abstract
A composition comprising an agonist of a 5-hydroxytryptamine (5-HT) receptor subtype 2A, 2B or 2C (5-HT2A, 5-HT2B or 5-HT2C), for the use in the treatment of a cognitive or neurological disorder in a patient, said patient having been pre-treated with naltrexone, or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine.
Claims19
A method of treating a cognitive or neurological disorder in a patient, said patient having been pre-treated with naltrexone, or a metabolite thereof or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine, comprising administering an agonist of a 5-hydroxytryptamine (5-HT) receptor subtype 2A, 2B or 2C (5-HT2A, 5-HT2B or 5-HT2C).
A method of treating a cognitive or neurological disorder in a patient, wherein said patient is also being administered or intended to be administered an agonist of a 5-hydroxytryptamine receptor subtype 2A, 2B or 2C (5-HT2A, 5-HT2B or 5-HT2C), the method comprising administering a composition comprising naltrexone, or a metabolite thereof, or an analogue selected from the group consisting of methylnaltrexone, nalmefene and nalorphine.
5-6. (canceled)
14-15. (canceled)
Dependencies are inferred from the claim text.